Lenalidomide beneficially alters IL-16 methylation status and IL-16 levels under rotenone insult in N9 cells

Abstract

The role of immune cells in the central nervous system and their interaction with peripheral monocytes are extensively investigated in the recent decade. Both animal models of parkinsonism and post-mortem studies demonstrated that peripheral immune cell recruitment occurs due to neuroinflammation seen in the Parkinson's disease pathology. Understanding these interaction mechanisms and possible modulators that have played a role in these processes is important for treatment options. As an immune anchor of the central nervous system, microglia are suggested to be one of the possible modulators of this interaction. IL-16 was recently described as a novel regulator for T cell recruitment and probably had a role in sporadic Parkinson's disease seen in the Chinese population. With the knowledge of epigenetic alterations in Parkinson's disease is seen in the immune cells, in the present study, we investigated possible changes in IL-16 levels with or without lenalidomide treatment in the rotenone-induced N9 microglial cells by enzyme-like immunosorbent assay (ELISA). Additionally, we also evaluated the methylation status of the IL-16 gene promoter after drug treatments by methylation specific-polymerase chain reaction (ms-PCR) analysis. Our results indicate that rotenone causes an increase in the IL-16 release, and lenalidomide attenuates that release in microglial cells. Additionally, rotenone changes the methylated status of IL-16 to unmethylated status, which explains increased IL-16 levels. However, lenalidomide treatment inhibited an increase in rotenone-induced IL-16 levels. Therefore, the present study suggests that lenalidomide improves the methylation status of IL-16 and prevented the increase in the IL-16 levels due to the rotenone insult.

Keywords

• Rotenone
• lenalidomide
• IL-16; methylation
• N9 cells
• Parkinson
• microglia.

References

1. [1] Lively S, Schlichter LC. Microglia responses to pro-inflammatory stimuli (LPS, IFNγ+TNFα) and reprogramming by resolving cytokines (IL-4, IL-10). Front Cell Neurosci. 2018; 12: 215. [CrossRef]
2. [2] Subramaniam SR, Federoff HJ. Targeting microglial activation states as a Therapeutic Avenue in Parkinson’s disease. Front Aging Neurosci. 2017; 9(JUN): 176. [CrossRef]
3. [3] Süß P, Hoffmann A, Rothe T, et al. Chronic Peripheral Inflammation Causes a Region-Specific Myeloid Response in the Central Nervous System. Cell Rep. 2020; 30(12): 4082-4095.e6. [CrossRef]
4. [4] Cruikshank WW, Kornfeld H, Center DM. Signaling and Functional Properties of lnterleukin-16. Int Rev Immunol. 1998; 16(42130): 523-540. [CrossRef]
5. [5] Almolda B, Costa M, Montoya M, González B, Castellano B. CD4 microglial expression correlates with spontaneous clinical improvement in the acute Lewis rat EAE model. J Neuroimmunol. 2009; 209(1-2): 65-80. [CrossRef]
6. [6] Bagyinszky E, Giau V Van, Shim K, Suk K, An SSA, Kim SY. Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci. 2017; 376: 242-254. [CrossRef]
7. [7] Mathy NL, Scheuer W, Lanzendörfer M, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology. 2000; 100(1): 63-69. [CrossRef]
8. [8] Skundric DS, Cruikshank WW, Drulovic J. Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis. J Neuroinflammation. 2015; 12(1): 78. [CrossRef]

9. [9] Liebrich M, Guo LH, Schluesener HJ, et al. Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch Immunol Ther Exp (Warsz). 2007; 55(1): 41-47. [CrossRef]
10. [10] Garretti F, Agalliu D, Arlehamn CSL, Sette A, Sulzer D. Autoimmmunity in parkinson’s disease: The role of α:-synuclein-specific T cells. Front Immunol. 2019; 10: 303. [CrossRef]
11. [11] Xiong N, Long X, Xiong J, et al. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson’s disease models. Crit Rev Toxicol. 2012; 42(7): 613-632. [CrossRef]
12. [12] Griñán-Ferré C, Corpas R, Puigoriol-Illamola D, Palomera-Ávalos V, Sanfeliu C, Pallàs M. Understanding Epigenetics in the Neurodegeneration of Alzheimer’s Disease: SAMP8 Mouse Model. J Alzheimer’s Dis. 2018; 62(3): 943-963. [CrossRef]
13. [13] Staszewski O, Prinz M. Glial epigenetics in neuroinflammation and neurodegeneration. Cell Tissue Res. 2014; 356(3): 609-616. [CrossRef]
14. [14] Martinez B, Peplow P. Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease. Neural Regen Res. 2018; 13(9): 1493-1506. [CrossRef]
15. [15] Cankara FN, Günaydın C, Bilge SS, Özmen Ö, Kortholt A. The neuroprotective action of lenalidomide on rotenone model of Parkinson’s Disease: Neurotrophic and supportive actions in the substantia nigra pars compacta. Neurosci Lett. 2020; 738: 135308.[CrossRef]
16. [16] Argente-Escrig H, Martinez JC, Gómez E, Balaguer A, Sevilla T, Bataller L. Lenalidomide induced reversible parkinsonism, dystonia, and dementia in subclinical Creutzfeldt-Jakob disease. J Neurol Sci. 2018; 393: 140-141. [CrossRef]
17. [17] Louveau A, Harris TH, Kipnis J. Revisiting the Mechanisms of CNS Immune Privilege. Trends Immunol. 2015; 36(10): 569-577. [CrossRef]
18. [18] Dantzer R. Neuroimmune interactions: From the brain to the immune system and vice versa. Physiol Rev. 2018; 98(1): 477-504. [CrossRef]
19. [19] Salimi H, Klein RS. Disruption of the Blood-Brain Barrier During Neuroinflammatory and Neuroinfectious Diseases. In: Neuroimmune Diseases. 2019: 195-234. [CrossRef]
20. [20] Ronaldson PT, Davis TP. Regulation of blood–brain barrier integrity by microglia in health and disease: A therapeutic opportunity. J Cereb Blood Flow Metab. 2020; 40(1_suppl): S6-S24. [CrossRef]
21. [21] Carrasco YR, Fleire SJ, Cameron T, Dustin ML, Batista FD. LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity. 2004; 20(5): 589-599. [CrossRef]
22. [22] Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinson’s disease. Mov Disord. 2012; 27(5): 597-607. [CrossRef]
23. [23] Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000; 67(6): 757-766. [CrossRef]
24. [24] Guo LH, Mittelbronn M, Brabeck C, Mueller CA, Schluesener HJ. Expression of interleukin-16 by microglial cells in inflammatory, autoimmune, and degenerative lesions of the rat brain. J Neuroimmunol. 2004; 146(1-2): 39-45. [CrossRef]
25. [25] Yang HY, Kim J, Kim SH, Choe CH, Jang YS. Pro-IL-16 is associated with MHC class II-mediated negative regulation of mouse resting B cell activation through MAP kinases, NF-κB and Skp2-dependent p27kip regulation. Scand J Immunol. 2013; 77(3): 177-186.[CrossRef]
26. [26] Sasaki M, Anast J, Bassett W, Kawakami T, Sakuragi N, Dahiya R. Bisulfite conversion-specific and methylation-specific PCR: A sensitive technique for accurate evaluation of CpG methylation. Biochem Biophys Res Commun. 2003; 309(2): 305-309. [CrossRef]